{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihpe5oto3yfp4lasq2cnvc2iy2w353jwkyd3saahptgco2nv3dqcu",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mfr75gx4xsy2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifx3w7l47kubpfmhtpjqlwjrebaw67tcgammtghusg2b5h7utl5km"
    },
    "mimeType": "image/jpeg",
    "size": 336489
  },
  "path": "/news/2026-02-glp-pill-orforglipron-outperforms-oral.html",
  "publishedAt": "2026-02-26T06:30:01.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Overweight & Obesity"
  ],
  "textContent": "A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 randomized controlled trial published in The Lancet. Additionally, participants taking orforglipron had significantly greater reductions in body weight than those taking oral semaglutide.",
  "title": "New GLP-1 pill orforglipron outperforms oral semaglutide in yearlong diabetes trial"
}